Establishing an in-silico medication towards treatment of Petit mal Epilepsy

Epilepsy is a neurological disorder. About 0.5%-1% of world population is affected by epilepsy.Petit mal epilepsy is the main seizure type in 15-20% of epileptic children. The mainstream intervention forpetit mal epilepsy is T-type Ca ++ channel blocker like ethosuximide. However, there is a need for safer andeffective drug. The protein-ligand interaction plays a significant role in structure based drug designing. In thepresent work we have taken t-type calcium channel as the target and identified natural compounds that canbe used against petit mal epilepsy. Here the drug ethosuximide is used as standard (E value = -132.35).Twelve natural compounds are retrieved from PubMed and are checked for drug likeness with bioinformaticstool ADMETox to satisfy Lipinski’s rule of five. Ten natural drugs qualify this step and are docked withreceptor using HEX docking software. All the compounds taken for docking were found to be better than theconventional drug, Ethosuximide.